Pharmacyte Biotech Revenue, Profits - PMCB Quarterly Income Statement

Add to My Stocks
$0.05 $0 (0%) PMCB stock closing price Sep 21, 2018 (Closing)

PMCB stock valuation based on fundamental analysis involves checking and analyzing financial statements and not just the Pharmacyte Biotech stock price. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has decreased from - to - and how operating and non operating activities have impacted the PMCB stock. The Pharmacyte Biotech profit and loss statement for 2019 Q1 shows a net profit of $-1.22M. Profits for last year was $-1.3M. Apart from this an investor should also check Pharmacyte Biotech assets and Pharmacyte Biotech free cash flow.

View and download details of revenue and profits for Pharmacyte Biotech for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is May - Apr2019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q4
Pharmacyte Biotech Revenues or Net Sales
----------
Cost Of Goods Sold (COGS)----------
Pharmacyte Biotech Gross Profit
----------
Research & Development Expense----------
Selling General & Admin Expense-1.21M1.22M1.29M1.26M----1.92M
Income Before Depreciation Depletion Amortization-1.22M-1.46M-2.03M-1.81M-1.68M-1.16M-1.28M-0.97M-1.03M-2.16M
Depreciation Depletion Amortization----------
Non Operating Income----------0.48M
Interest Expense----------
Pharmacyte Biotech Pretax Income
-1.22M-1.3M-2.03M-1.81M-1.68M-1.16M-1.28M-0.97M-1.03M-2.64M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-1.22M-1.3M-2.03M-1.81M-1.69M-1.16M-1.28M-0.98M-1.03M-1.12M
Extraordinary Items & Discontinued Operations----------
Pharmacyte Biotech Profit/ Loss (Net Income)
-1.22M-1.3M-2.03M-1.81M-1.69M-1.16M-1.28M-0.98M-1.03M-1.12M
Average Shares used to compute Diluted EPS1.05B1.02B975.85M973.17M925.58M884.99M859.53M848.91M788.17M778.89M
Average Shares used to compute Basic EPS1.05B1.02B975.85M973.17M925.58M884.99M859.53M848.91M788.17M778.89M
Income Before Nonrecurring Items-1.22M-1.3M-2.03M-1.81M-1.69M-1.16M-1.28M-0.98M-1.03M-1.12M
Income from Nonrecurring Items----------
Pharmacyte Biotech Earnings Per Share Basic Net
0.00-0.010.000.000.000.000.000.000.000.00
Pharmacyte Biotech Earnings Per Share Diluted Net
0.00-0.010.000.000.000.000.000.000.000.00
EPS Diluted Before Nonrecurring Items0.000.000.000.000.000.000.000.000.000.00
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Pharmacyte Biotech stock analysis. It helps to look at the following income statement items:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $- for this quarter of 2019 Q1. Our Pharmacyte Biotech revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-1.22M for PMCB stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called the profit and loss statement. Apart from the PMCB income statement, one can check the Pharmacyte Biotech historical stock prices to check how the price has moved with time.

Pharmacyte Biotech Income Statement - Key Financial Ratios

Operating Margin
0
Net Profit Margin
0